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Abstract
The Immune Epitope Database (IEDB), at www.iedb.org, has the mission to make pub-
lished experimental data relating to the recognition of immune epitopes easily available
to the scientific public. By presenting curated data in a searchable database, we have
liberated it from the tables and figures of journal articles, making it more accessible and
usable by immunologists. Recently, the principles of Findability, Accessibility,
Interoperability and Reusability have been formulated as goals that data repositories
should meet to enhance the usefulness of their data holdings. We here examine how the
IEDB complies with these principles and identify broad areas of success, but also areas
for improvement. We describe short-term improvements to the IEDB that are being im-
plemented now, as well as a long-term vision of true ‘machine-actionable interoperabil-
ity’, which we believe will require community agreement on standardization of know-
ledge representation that can be built on top of the shared use of ontologies.
Introduction
Recently, the principles of Findability, Accessibility,
Interoperability and Reusability (FAIR; Textbox 1) have
been formulated as critical goals that data repositories
should meet to enhance the usefulness of their data hold-
ings (1). These principles were established by a diverse
group of academic and private community members with a
particular emphasis on enhancing the ability of machines
to automatically find and use data (Textbox 2). The au-
thors of the FAIR data principles call on all data producers
and publishers to examine and implement these principles
and there is good indication that funding agencies
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and journals will increasingly require adherence to such
principles.
Following the example of other responsible databases
such as UniProt (2), we wanted to assess how well the
Immune Epitope Database (IEDB) (3) currently adheres to
FAIR principles and how it could be further improved. In
this context, it is important to note some characteristics of
the IEDB in order to understand how it compares to other
knowledge resources. The IEDB is a publically available
database of experiments demonstrating recognition of im-
mune epitopes by adaptive immune receptors. The IEDB
was established in 2004 and provides access to over a million
experiments manually curated from>18 500 journal art-
icles, as well as data directly submitted by the community.
The atomic unit of curation in the IEDB is an assay (i.e. an
experiment) in which the immune recognition of an epitope
is tested. Figure 1 gives an abbreviated example of data asso-
ciated with one assay in the IEDB. The structured description
of each experiment encompasses up to 400 database fields
describing (i) the source of the information about the experi-
ment (‘Reference’), (ii) the epitope structure itself (‘Epitope’),
(iii) immune history of the host from whom samples are
tested for recognition of the epitope (‘Immunization’) and
(iv) the experimental techniques and type of immune re-
sponse measured (‘Assay’). By structuring the free text infor-
mation from the literature into the IEDB format, users can
systematically query for experiments by many aspects of the
data. For example, one can search by features of the host,
such as experiments that were conducted using samples from
Hepatitis C virus infected humans, as well as by features of
what was measured, such as interferon gamma production
by T cells in response to peptide epitopes.
The IEDB was designed primarily for human users query-
ing through the website interface. Moreover, our user com-
munity predominantly consists of experimental scientists, so
most of the effort to date has gone into making the query
Textbox 1: The FAIR principles as stated in the study by Wilkinson et al. (1)
To be Findable:
F1. (meta)data are assigned a globally unique and persistent identifier
F2. data are described with rich metadata (defined by R1 below)
F3. metadata clearly and explicitly include the identifier of the data it describes
F4. (meta)data are registered or indexed in a searchable resource
To be Accessible:
A1. (meta)data are retrievable by their identifier using a standardized communications protocol
A1.1 the protocol is open, free, and universally implementable
A1.2 the protocol allows for an authentication and authorization procedure, where necessary
A2. metadata are accessible, even when the data are no longer available
To be Interoperable:
I1. (meta)data use a formal, accessible, shared, and broadly applicable language for knowledge representation.
I2. (meta)data use vocabularies that follow FAIR principles
I3. (meta)data include qualified references to other (meta)data
To be Reusable:
R1. meta(data) are richly described with a plurality of accurate and relevant attributes
R1.1. (meta)data are released with a clear and accessible data usage license
R1.2. (meta)data are associated with detailed provenance
R1.3. (meta)data meet domain-relevant community standards
Textbox 2: FAIR goals for machine actionable data objects as stated in the study by Wilkinson et al. (1)
“The agent (. . .) [should] have the capacity, when faced with a digital object never encountered before, to (i) identify the
type of object (with respect to both structure and intent); (ii) determine whether it is useful within the context of the
agent’s current task by interrogating metadata and/or data elements; (iii) determine whetherit is usable, with respect to
license, consent or other accessibility or use constraints; and (iv) take appropriate action, in much the same manner
that a human would.”
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and reporting interfaces accessible without any advanced
computational skills. We were thus expecting that the cur-
rent IEDB implementation might not live up to the highest
standards of the FAIR principles and especially concerning
the machine action ability (Textbox 2) of our data. At the
same time, throughout the last 10 year, significant effort has
been made to make the IEDB data more computable. This
was done to utilize automated inferences for data validation,
to enable advanced query interfaces (4) and also to improve
links from the IEDB to other knowledge repositories (5).
Accordingly, we here conducted a review of the IEDB’s
compliance with FAIR principles to provide a real life ex-
ample of the degree of compliance of an existing resource,
to identify areas of non-compliance and also to explore how
Row # 
1 Reference ID 1001817
2 Reference Type Literature
3 PubMed ID 11920289
4 Arcle Authors
Angus J MacDonald; Margaret Duffy; Miriam T Brady; Susan McKiernan; William Hall; 
John Hegarty; Michael Curry; Kingston H G Mills
5 Arcle Title
CD4 T helper type 1 and regulatory T cells induced against the same epitopes on the 
core protein in hepas C virus-infected persons.
6 Date 2002
7 Journal J Infect Dis
8 Epitope ID 717
9 Chemical Type Linear pepde
10 Linear Sequence ADLMGYIPLVGAPLGGAARA
11 Source Molecule Name polyprotein
12 Source Accession BAA03375.1
13 Source Organism ID 31647
14 Source Organism Hepas C virus subtype 1b
15 Locaon of Data in Reference Figure 1
16 Immunizaon Comments
PBMC were harvested from a group of Irish women infected with HCV 1b through the 
administraon of contaminated an-D Ig.
17 Host Organism ID 9606
18 Host Organism Homo sapiens
19 Sex F
20 Age 41-55
21 In Vivo Process Type Occurrence of infecous disease
22 Disease Code 171
23 Disease State hepas C
24 Disease Stage Chronic;
25 Epitope Relaon Source Organism
26 Object Type Organism
27 Organism ID 31647
28 Organism Hepas C virus subtype 1b
29 Assay Comments by IEDB Curator
PBMC from HCV infected paents produced IFNg in response to the epitope. 
Chronically infected paents (HCV PCR+) responded more oen than paents who 
cleared the virus (HCV RNA-).
30 Qualitave Measurement Posive
31 Method/Technique ELISA
32 Measurement of IFNg release
33 Locaon of Assay Data in Reference Figure 2 and table 1
34 Effector Cell Tissue Type Blood
35 Effector Cell Type PBMC
36 Epitope Relaon Epitope
37 Chemical Type Linear pepde
38 Linear Sequence ADLMGYIPLVGAPLGGAARA
Antigen
Host
Immunization (Sample origin)
1st In Vivo Process
1st Immunogen
T Cell Assay (Experiment performed)
Effector Cells
Reference (source of information)
Epitope
Figure 1. Abbreviated IEDB record for one assay. The data shown are an abbreviated version of the IEDB record for http://www.iedb.org/assay/
1288921. The record is separated into sections (e.g. Reference, Epitope, Immunization), and subsections (e.g. Host within the Immunization section).
The leftmost column contains a numeric ID for ease of reference in this manuscript that is not part of the IEDB. A representative subset of 38 of the ori-
ginal 63 data rows of the record are displayed, and some rows were re-ordered to improve readability of this table.
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the FAIR principles might be adjusted and fine-tuned to fur-
ther improve their usefulness.
Results
Several of the FAIR principles (e.g. F2 in Textbox 1) make a
distinction between data and metadata. This distinction
makes immediate sense for knowledge repositories that store
raw data in a standardized format, such as sequence reads
in FASTQ format in the Sequence Read Archive (SRA) (6)
or Flow Cytometry Standard files in FlowRepository (7).
Such ‘data’ must be accompanied with ‘metadata’ on how
the data were generated. For example, in the case of an SRA
deposition, information on what sample was being
sequenced would be considered ‘metadata’, and specific se-
quence reads would be considered ‘data’. However, in the
case of the information stored in the IEDB, there is no separ-
ation between data and metadata. Arguably, the IEDB
stores only metadata, and the raw data can be found in the
original journal article, typically in the form of figures or
tables that follow no specific convention. In the following,
we will thus interpret FAIR principles that explicitly refer to
‘data’ as applying to the information in the original journal
articles, and to ‘metadata’ as the information stored in the
IEDB database fields.
Principle F: findable
There are four items (F1–F4, textbox 1) spelling out the
principle of findability. We will address each of these items
in the following paragraphs, starting each paragraph by re-
peating the principle as stated in Textbox 1 in italics and
an assessment how the IEDB currently adheres to the prin-
ciple and, if applicable, how the IEDB can be improved.
F1: (meta)data are assigned a globally unique and
persistent identifier
The IEDB assigns unique identifiers, with the most funda-
mental being the identifier for a specific assay. For ex-
ample, URL http://www.iedb.org/assay/1288921 identifies
the IEDB record for the experiment displayed in Figure 1.
In addition, a collection of assays curated from a single ref-
erence has a separate identifier. For example, http://www.
iedb.org/reference/1001817 identifies the set of 34 assays
curated from the journal article that included the experi-
ment in Figure 1. By utilizing the full uniform resource
locator (URL) as the identifier, we ensure that the identifier
is globally unique, and that someone with an identifier can
find more information about the resource using a web
browser or other common tools. CURIE syntax can be
used to define a mapping from ‘IEDB_ref’ to the URL
http://www/iedb.org/reference/, allowing two-way
translation between the CURIE ‘IEDB_ref: 1001817’ and
the full URL http://www.iedb.org/reference/1001817. This
gives us all the benefits of a compact ID and a findable
URL. In terms of persistence, the IEDB is committed to re-
tain these identifiers, and if there are changes to the identi-
fier scheme, to utilize HTTP redirects to ensure that the
URLs will continue to resolve. While there are dependen-
cies on the continued control of the iedb.org domain name
for long-term persistence, we believe that scenarios in
which the IEDB continues to be available, but the domain
does not are highly unlikely. Thus, we believe that the
IEDB does follow the principles articulated in F1.
F2: data are described with rich metadata (defined by R1
below)
As explained earlier, the IEDB is a metadata repository, so
striving to meet principle F2 is at the heart of its mission.
How metadata is chosen is described in our response to R1
below.
F3: metadata clearly and explicitly include the identifier of
the data it describes
The IEDB identifies the data being described by linking to
the relevant journal publication in terms of citation infor-
mation (journal, author, title, year, volume, pages, etc.)
and more importantly for machine readable linkage, by the
PubMed ID. In addition, the specific location in the journal
article in which the curated information for the specific
epitope and assay was found is described in separate data-
base fields (Rows #15 and 33 in Figure 1). However,
encoding the location in the journal article is currently
done in free text. An improvement that is currently under-
way is to standardize the content of this field with the ul-
timate goal of using a structured vocabulary such as an
ontology to describe locations in the journal article or pos-
sibly using anchor tags in the text or xml.
The data shown are an abbreviated version of the IEDB
record for http://www.iedb.org/assay/1288921. The record
is separated into sections (e.g. Reference, Epitope and
Immunization) and subsections (e.g. Host within the
Immunization section). The leftmost column contains a nu-
meric ID for ease of reference in this manuscript that is not
part of the IEDB. A representative subset of 38 of the ori-
ginal 63 data rows of the record are displayed, and some
rows were re-ordered to improve readability of this table.
F4: (meta)data are registered or indexed in a searchable
resource
The IEDB itself is an indexed, searchable resource of IEDB
records. However, this principle is presumably intended
for users (or machines) that are not aware that the IEDB
exists, which necessitates discoverability of the IEDB data
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without knowledge of the IEDB itself. For our targeted
user community of immunologists, we have performed
user surveys, interviews and inspection of IEDB website ac-
cess logs which identified that the main ways that our users
become aware of the IEDB are (i) being pointed directly to
the IEDB by reading a journal article mentioning it, (ii)
general web-search engines, such as Google and (iii) links
from immunology related knowledge repositories, such
as the related Bioinformatics Resource Centers (BRC) (8)
or the National Center for Biotechnology Information
(NCBI) taxonomy (9). In terms of the FAIR goal of being
findable by machines, only item (iii) of interlinking with
related knowledge resources is helpful. To improve upon
this, we have indexed IEDB data in Biosharing (10) and
have submitted IEDB data to two websites specifically in-
tended for machine discoverability, namely bioCADDIE
(11) and Wikidata (12).
Principle A: Accessible
There are two main items for the principle of accessibility,
A1 and A2. A1 is further subdivided into two parts: ‘A1.
(meta)data are retrievable by their identifier using a stand-
ardized communications protocol’, ‘A1.1 the protocol is
open, free, and universally implementable’, ‘A1.2 the
protocol allows for an authentication and authorization
procedure, where necessary’. The main protocol used to
obtain data from the IEDB is simply through HTTP. No
authentication is required to access IEDB data. While this
means that the IEDB satisfies this FAIR principle to the let-
ter, it does not do so in regards to the data being optimally
machine actionable as defined in Textbox 2: Implementing
machine access to IEDB data over the HTML interface in-
tended for human users would require ‘screen scraping’ the
information from the IEDB web pages, which is inherently
error-prone and unstable. There are alternatives to access
IEDB data, namely to (i) export a set of query results in
spreadsheet format and to (ii) download the entirety of the
IEDB either in XML format or as a SQL database. While
these alternative formats are more machine readable, an
automated agent inspecting an IEDB data record as identi-
fied in Figure 1 would not be aware that alternative rep-
resentations are available. Thus, a representation of the
IEDB assay records that is better suited for machine read-
ability should be provided, as outlined in the Long-term
vision section of the discussion. We have begun adding
machine-readable metadata to our IEDB web pages, begin-
ning with provenance data. The metadata is encoded in
JSON-LD format (13), following Google’s structured data
recommendations, and can be easily translated into other
concrete Resource Description Framework (RDF) formats.
We plan to build on this incrementally, including more of
the human-readable content of our web pages in machine-
readable format.
The second principle for accessibility is A2. ‘metadata
are accessible, even when the data are no longer available’.
Given that the data referred to in the IEDB is from pub-
lished journal articles, we have not yet experienced cases
where the data source was no longer available. Even in the
case of a retracted journal article, a copy of said article
would still be available, but marked as retracted (or
redacted) by PubMed. The metadata captured in the IEDB
would remain available in either case. To date, we have
not annotated these records as belonging to a retracted art-
icle, but will begin doing so in the near future.
Principle I: Interoperable
I1: (meta)data use a formal, accessible, shared, and
broadly applicable language for knowledge representation
The IEDB uses standard database tables which essentially
consist of key: value pairs to represent its information.
There is implicit semantic meaning of how the different val-
ues in an IEDB record interrelate. This typically poses less
problems for humans, as contextual clues will, e.g. make it
obvious that fields such as disease code, disease state and
disease stage (Figure 1, rows 22–24) are interrelated. But a
machine would not be able to reliably make this inference.
To address this issue, an explicit representation of this infor-
mation using RDF/OWL is under development, as discussed
is the Long-term vision section of the discussion.
I2: (meta)data use vocabularies that follow FAIR
principles
Whenever possible, the IEDB utilizes externally developed
vocabularies to describe a given domain, primarily through
the use of open biomedical ontologies (OBO) Foundry
ontologies (14). The principles and practices of the OBO
Foundry ensure that member ontologies are findable
through the OBO registry, accessible through standardized
interfaces, interoperable through the common use of the
OWL standard and reproducible through the persistent
availability of versioned copies of ontologies over time. If
an existing OBO ontology in a domain does not provide a
term needed by the IEDB, we submit new term requests.
This improves both the IEDB data and enriches the ontolo-
gies we utilize. For example, the IEDB has contributed
>300 terms to ontology for biomedical investigations
(OBI) (15), >200 terms to the disease ontology (16),
and>2400 terms to Chemical Entities of Biological
Interest (17), among others. There are, however, several
areas where currently no standards are available to repre-
sent data needed by the IEDB, either within the OBO
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Foundry or outside of it. In some cases, such as with major
histocompatibility complex (MHC) restriction, the IEDB
team developed its own ontology, as in the MHC
restriction ontology (18).
There are a number of shortcomings in the way vocabu-
laries are used by the IEDB. First of all, the use of external
vocabularies is not consistently indicated to external users.
For example, row 31 in which the method/technique of the
experiment is specified as ‘ELISA’ refers to a class defined in
OBI (http://purl.obolibrary.org/obo/OBI_0000661) and the
value for what is being measured in row 32 (‘IFNg release’)
is referring to a term in the gene ontology (http://purl.oboli
brary.org/obo/GO_0032609). This must be made explicit to
external users in a consistent fashion, so that every ‘value’ in
a key-value pair has both a textual value and a URL resolv-
ing to a machine readable term, ideally from externally
defined vocabularies. We will implement a consistent way
of communicating where linkable identifiers refer to specific
terms. We are considering utilizing RDFa to add attribute-
level extensions to our HTML in the web pages in order to
convey that the term on the page is from a formal ontology
and comes with its own rich metadata.
Second, for a limited number of IEDB fields, no external
vocabularies have been identified. In these cases, the IEDB
uses list values that are not externally accessible and therefore
do not comply with FAIR principles. In several instances, we
anticipate the emergence of useful annotations, submitting
our data to external groups ahead of the existence of stable
identifiers, such as with inbred laboratory organisms that
NCBI taxonomy does not cover. For example, we are await-
ing stable identifiers for rat strains from the Rat Genome
database (19) and for mouse strains from Mouse Genome
Informatics (20). We have submitted our list of needs to
both groups and will be ready to incorporate their official
identifiers as soon as they are released. We are also currently
working with the iPTMnet (21) to obtain formal identifiers
for post-translational modifications (PTMs) of proteins and
are always open to opportunities to better identify and anno-
tate proteins found in our data. While we continue to rely on
external vocabularies, in the cases when no external vocabu-
laries have been identified, we strive to clarify their meaning
and make the IEDB internal definitions of these terms expli-
cit. Definitions for these terms are provided to the public in
the IEDB curation manual (22) but could be made more ex-
plicit. We have also recently made these potentially tempor-
ary terms available as part of the ontology for immune
epitopes (ONTIE) (23).
I3: (meta)data include qualified references to other
(meta)data
The OBO family of ontologies makes a large number of se-
mantically explicit cross-references to other ontologies.
Uusing OBO ontology terms in its metadata annotation,
the IEDB connects to this rich network of metadata.
Principle R: Reusable
R1: meta(data) are richly described with a plurality of
accurate and relevant attributes
The IEDB metadata representation is extremely detailed,
describing individual experiments with up to 400 attri-
butes. The data shown in Figure 1 are a shortened ex-
ample. The relevance and accuracy of the attributes are
checked by both a manual review process as part of our
curation pipeline and automated validation checks inte-
grated into the curation interface (22).
R1.1: (meta)data are released with a clear and accessible
data usage license
The IEDB was failing in this principle when we began this
analysis, as no license was specified. We have since
addressed this shortcoming by including human read-
able licensing information for the Creative Commons
Attribution 4.0 International (CC BY 4.0, https://creative
commons.org/licenses/by/4.0/) license and will be adding
machine-readable licensing information, both at the web-
site level and at the level of individual assay records
shortly, using the ‘license’ predicate from the Dublin Core
Metadata Initiative (24).
R1.2: (meta)data are associated with detailed provenance
There are two aspects of provenance to the IEDB meta-
data. First is the original data source that was curated by
the IEDB, which is specified using PubMed identifiers and
locations within the journal article as described in F3. In
addition, the IEDB should state that the information
entered as metadata for a given publication was authored
by an IEDB curator. This was implied but not explicitly
stated. We added this additional provenance information
to the IEDB assay and reference web pages using the
provenance authoring and versioning ontology (25),
embedding it as machine-readable data in JSON-LD for-
mat, following Google’s structured data guidelines.
R1.3: (meta)data meet domain-relevant community
standards
The domain of the IEDB is immunological investigations
of epitope reactivity. There were no formal standards es-
tablished in this specific area, so the design, implementa-
tion, and curation guidelines of the IEDB were instead
vetted by the scientific immunology community through
interactions with domain experts, publications, and
outreach activities, including conference booths, annual
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workshops, and user surveys. As stated earlier, elements of
the IEDB are expressed using external metadata standards,
such as the use of the NCBI taxonomy to describe organ-
ism species.
IEDB modifications to enhance compliance with
FAIR principles
The short-term improvements that the IEDB could imple-
ment to better comply with FAIR principles are summar-
ized in Table 1. The Long-term vision of how a truly
machine-actionable data repository could be implemented,
which will require extensive additional prototyping and
coordination with other knowledge resource providers are
detailed in the ‘Discussion’ section.
As listed in Table 1, we have identified eight areas for
improvement of the IEDB that we began implementing in
2016 and expect to complete by the middle of 2018:
F3: Identification of journal figures and tables
• We identified patterns (e.g. ‘Figure X’) and common
term composition rules (e.g. ‘Figure X and Table Y;, or
‘Figure X, Table Y’) for location of data in figures
• We developed a canonical representation and are transi-
tioning data to this format
• We will implement validation rules enforcing a format
that is convertible to canonical
• We will identify an ontology that covers journal article
parts used in IEDB location fields
• We will add URLs to ontology in addition to free text
F4: Add IEDB data to external resources
• IEDB has been indexed by Biosharing
• IEDB datasets have been sent to Biocaddie and modeling
is in process
• Relevant IEDB links and datasets have been identified by
Wikidata collaboration and their implementation is in
progress
I2: Make all links to external vocabularies explicit
• We will standardize the format of lookup tables
• We will consistently report values with textual label and
link to external resources
• We have enabled exports with external identifiers
I2: Make all internal vocabularies public via ONTIE
and link to them
• We have identified all values in the IEDB tables not taken
from external vocabularies
• We have assigned each an ONTIE identifier
• We will organize ONTIE terms in passable hierarchy
• We have registered ONTIE for PURLs
R1.1: Include licensing information with the IEDB
records
• We identified the Creative Commons Attribution 4.0
International License as appropriate for IEDB data
• Human readable licensing info
rmation has been added to the IEDB download and cit-
ation sections
• We will add human and machine readable licensing in-
formation to the IEDB assay and reference pages
R1.2: Include provenance information regarding
IEDB curation
• We added machine-readable provenance information in
JSON-LD to the IEDB assay and reference pages
Discussion
We systematically inspected the IEDB for adherence to
the FAIR principles. Overall, the IEDB does comply with
a number of the FAIR principles to a high standard, but
at the same time, several areas for improvement were
identified. Inspection of the IEDB for compliance to the
well-argued FAIR principles enabled the IEDB team to
Table 1. Planned improvements of the IEDB to better adhere to FAIR standards
FAIR principle Steps to improve IEDB compliance Completion Date
F3 Standardize identification of journal parts (figures/tables) 10/2017
F4 Add IEDB metadata to Biosharing, Biocaddie and Wikidata 10/2017
A1 Provide machine actionable representation of IEDB assay level data ?
I1 Represent the IEDB data in RDF/OWL ?
I2 Make all links to external vocabularies explicit 06/2017
I2 Make all internal vocabularies public via ONTIE and link to them 06/2017
R1.1 Include licensing information with the IEDB records 12/2016
R1.2 Include provenance information regarding IEDB curation 12/2016
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take an outside viewpoint of the IEDB which helped to
identify weaknesses that were not clearly apparent to
those involved in the development and day-to-day oper-
ation of the database. Conversely, it was apparent to us
that improvements could be made in the formulation of
FAIR principles, to facilitate understanding of what spe-
cifically each principle was meant to address, and how
each principle differentiates from the other principles. For
example, a definition of what is considered ‘data’ vs.
‘metadata’ can be found in a related publication (26), but
it is not clear if this is the official FAIR definition, or al-
ternatively if this distinction could be altogether elimi-
nated. Likewise, an additional document, distinct from
the FAIR publication, clearly detailing each of the FAIR
principles with examples of adherence and non-adherence
would be key to facilitate widespread implementation
and adherence to the principles. Additional documenta-
tion in existence on various web sites does not match the
numbering or wording of the published principles, so it
becomes paradoxically ambiguous what it means to ‘ad-
here to FAIR principles’ when using those secondary
sources. Recent FAIR publications and use cases (2, 26,
and 27) continue to clarify what FAIR really means and
we expect that as more practical applications of FAIR
principles are performed, increasingly more of the ambi-
guity of ‘FAIRness’ will be resolved. We hope that our in-
terpretation of these principles will also contribute to the
general understanding.
Long-term vision
A truly machine-actionable data repository, in which an auto-
mated agent for the first time encountering the repository can
inspect it and act like a human would (Textbox 2), will re-
quire substantial additional work beyond the implementation
of FAIR principles. Specifically, even if two knowledge re-
sources use the same syntactic representation (e.g. RDF/
OWL) and utilize the same vocabularies (e.g. OBO Foundry
ontologies), in our experience interoperability on a machine
level will still be difficult to achieve. For example, because of
limitations of OWL not being expressive enough, it is difficult
to ensure that a computer understands how different model-
ing schemes refer to the same object. To achieve this goal will
require establishing a set of conventions that can be validated
to ensure that a machine will understand content modeled by
different sets of people.
For example, if the PHI-base pathogen–host interaction
database (28) extracts host: pathogen information and the
IEDB contains the very same information, but models it in
an incompatible way, an automated agent would not be
able to determine that the information is in fact the same.
Neither model is necessarily right or wrong, but they
would need to be manually coordinated and resolved be-
fore automation would be possible.
We suggest that the effort involved in OBO Foundry
ontology creation is also the best venue to provide guid-
ance on how to model statements using OBO Foundry
terms. We are in the process of actively coordinating the
modeling of datasets in different NIAID funded reposito-
ries already committed to using OBO Foundry ontologies.
Specifically, these include the BRCs (8), the IEDB and
ImmPort (29). We plan to use this as a proof of principle
on how to cross-integrate data from different ontologies
towards the future goal of a truly machine-actionable
data repository.
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